Education
About Us
Working with TipRanks
Follow Us
Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
RESEARCH TOOLSreports
AUROPHARMA Analyst Ratings
Moderate Buy
10 Buy
1 Hold
3 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AUROPHARMA Stock 12 Month Forecast
Average Price Target
₹1,299.00
▲(21.48% Upside)
| Highest Price Target₹1,560 | Average Price Target₹1,299 | Lowest Price Target₹1,010 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
₹1,261
Buy
17.92%
Upside
Reiterated
08/01/25
Aurobindo Pharma's overall score is driven by strong financial performance, characterized by robust revenue growth and improved profitability, supported by solid cash flow management. The stock's valuation is reasonable, but technical indicators suggest neutral market momentum, reflecting mixed investor sentiment.
ICICI Securities
₹1,330→₹1,300
Buy
21.57%
Upside
Upgraded
08/06/25
Citi
₹1,100→₹1,010
Sell
-5.55%
Downside
Reiterated
08/06/25
Goldman Sachs
₹1,275→₹1,250
Buy
16.89%
Upside
Reiterated
07/15/25
Macquarie
₹1,700→₹1,010
Buy
-5.55%
Downside
Reiterated
07/08/25
Nuvama
₹1,485→₹1,460
Buy
36.53%
Upside
Reiterated
06/27/25
Kotak Mahindra
₹1,145→₹1,100
Sell
2.87%
Upside
Reiterated
05/28/25
Motilal Oswal
₹1,370
Buy
28.12%
Upside
Reiterated
05/28/25
HSBC
₹1,395→₹1,415
Buy
32.32%
Upside
Reiterated
05/28/25
Bank of America Securities
₹1,480→₹1,350
Buy
26.24%
Upside
Reiterated
05/27/25
UBS
₹1,333→₹1,200
Sell
12.22%
Upside
Reiterated
05/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
₹1,261
Buy
17.92%
Upside
Reiterated
08/01/25
Aurobindo Pharma's overall score is driven by strong financial performance, characterized by robust revenue growth and improved profitability, supported by solid cash flow management. The stock's valuation is reasonable, but technical indicators suggest neutral market momentum, reflecting mixed investor sentiment.
ICICI Securities
₹1,330→₹1,300
Buy
21.57%
Upside
Upgraded
08/06/25
Citi
₹1,100→₹1,010
Sell
-5.55%
Downside
Reiterated
08/06/25
Goldman Sachs
₹1,275→₹1,250
Buy
16.89%
Upside
Reiterated
07/15/25
Macquarie
₹1,700→₹1,010
Buy
-5.55%
Downside
Reiterated
07/08/25
Nuvama
₹1,485→₹1,460
Buy
36.53%
Upside
Reiterated
06/27/25
Kotak Mahindra
₹1,145→₹1,100
Sell
2.87%
Upside
Reiterated
05/28/25
Motilal Oswal
₹1,370
Buy
28.12%
Upside
Reiterated
05/28/25
HSBC
₹1,395→₹1,415
Buy
32.32%
Upside
Reiterated
05/28/25
Bank of America Securities
₹1,480→₹1,350
Buy
26.24%
Upside
Reiterated
05/27/25
UBS
₹1,333→₹1,200
Sell
12.22%
Upside
Reiterated
05/27/25
Best Analysts Covering Aurobindo Pharma Ltd
1 Month
xxx
Success Rate
1/2 ratings generated profit
Average Return
+0.50%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +0.50% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+4.27%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +4.27% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
+5.70%
reiterated a sell rating 3 days ago
Copying Vivek Agrawal CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.70% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
Average Return
+5.70%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +5.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AUROPHARMA Analyst Recommendation Trends
Rating
Mar 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
6
11
11
14
11
Hold
0
1
1
1
0
Sell
1
4
4
3
1
Strong Sell
0
0
0
0
0
total
7
16
16
18
12
Each month's total comprises the sum of three months' worth of ratings.
AUROPHARMA Financial Forecast
AUROPHARMA Stock Forecast FAQ
What is IN:AUROPHARMA’s average 12-month price target, according to analysts?
Based on analyst ratings, Aurobindo Pharma Ltd’s 12-month average price target is 1,299.00.
What is IN:AUROPHARMA’s upside potential, based on the analysts’ average price target?
Aurobindo Pharma Ltd has 21.48% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Aurobindo Pharma Ltd a Buy, Sell or Hold?
Aurobindo Pharma Ltd has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 1 hold ratings and 3 sell ratings.
What is Aurobindo Pharma Ltd’s share price target?
The average share price target for Aurobindo Pharma Ltd is 1,299.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹1,560.00 ,and the lowest forecast is ₹1,010.00. The average share price target represents 21.48% Increase from the current price of ₹1,069.35.
The highest analyst share price target is ₹1,560.00 ,and the lowest forecast is ₹1,010.00. The average share price target represents 21.48% Increase from the current price of ₹1,069.35.
What do analysts say about Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of Aurobindo Pharma Ltd?
To buy shares of IN:AUROPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.